Becton, Dickinson and Company $BDX Holdings Increased by Glenview Trust Co

Glenview Trust Co raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 76,949 shares of the medical instruments supplier’s stock after acquiring an additional 4,707 shares during the quarter. Glenview Trust Co’s holdings in Becton, Dickinson and Company were worth $13,774,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BDX. Maryland Capital Advisors Inc. raised its holdings in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 139 shares during the last quarter. Trifecta Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 62 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $29,000. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BDX. Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Wolfe Research assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating on the stock. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Bank of America increased their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $185.07.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Trading Down 0.4%

Shares of BDX opened at $197.48 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $200.47. The business has a 50-day moving average of $186.58 and a 200 day moving average of $170.26. The firm has a market cap of $54.41 billion, a P/E ratio of 59.48, a price-to-earnings-growth ratio of 13.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.